Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges | American Society of Clinical Oncology Educational Book
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Nature Reviews Cancer
The critical features, traditional evaluation criteria, and the... | Download Scientific Diagram
Frontiers | Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation - ScienceDirect
Cancer immunotherapy: it's time to better predict patients' response | British Journal of Cancer
Predictive and Prognostic Biomarkers of Clinical Relevance | OncologyPRO
Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? - ecancer
Biomarkers for Immunotherapy: Current Developments and Challenges | American Society of Clinical Oncology Educational Book
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine - ScienceDirect
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context - ScienceDirect
Elevated tumor markers for monitoring tumor response to immunotherapy - eClinicalMedicine
Cancers | Free Full-Text | Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors | Biomarker Research | Full Text
Predictive biomarkers for checkpoint inhibitor-based immunotherapy - The Lancet Oncology
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
High IL-8 correlates with reduced response to PD-1/PD-L1 checkpoint blockade
Frontiers | FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee - ScienceDirect
Frontiers | From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association | Nature Communications
Frontiers | Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
